Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyMHN acalabrutinib (Calquence) Coverage Update | Op…
    Ask Trek AI about this page
    ModifiedmhnPolicy CP.PHAR.366

    Acalabrutinib (Calquence) coverage

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.366 alerts

    Get alerted when Policy CP.PHAR.366 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and prior authorization criteria for acalabrutinib (Calquence) for adult patients with mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and selected off-label B-cell malignancies; applies to providers and members covered under the payer's Commercial, HIM and Medicaid lines of business.

    Policy Summary
    Payermhn
    PolicyAcalabrutinib (Calquence) coverage
    Policy CodePolicy CP.PHAR.366
    Change TypeMaterial updates (NCCN alignment, auth duration)
    Effective Date
    Next Review Date
    Key ActionPrescriber must submit documentation (office chart notes, lab results, or other clinical information) supporting that the member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Added NCCN-supported use: first-line therapy for CLL/SLL in combination with venetoclax (Venclexta).

    Updated initial authorization durations from 6 months to 12 months for Medicaid/HIM.

    Updated conditions for first-line use in CLL/SLL to align with recent FDA approval adding AMPLIFY trial results to the Calquence PI.

    Added tablet formulation dosing/regimen language and tablet product availability.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    100 mg PO BIDTypical dosing regimen (MCL, CLL/SLL)
    400 mg/dayMaximum daily dose
    12 monthsStandard approval duration
    14 cyclesMax total cycles with venetoclax
    Tablet & CapsuleAvailable formulations

    Coverage Criteria

    Initial Therapy: Mantle Cell Lymphoma

    Covered when ALL of the following are met

    MCL initial: 1. Diagnosis of mantle cell lymphoma (MCL). 2. Prescribed by or in consultation with an oncologist or hematologist. 3. Age ≥ 18 years. 4. For Calquence requests, member must use generic acalabrutinib if available unless contraindicated or clinically significant adverse effects are experienced. 5. Member does not have Imbruvica-refractory MCL with BTK C481S mutations. 6. Member meets one of the following: (a) received ≥1 prior therapy; OR (b) meets one of: (i) prescribed in combination with bendamustine and rituximab and is ineligible for autologous HSCT; (ii) prescribed in combination with rituximab for less aggressive induction therapy; (iii) prescribed in combination with rituximab as pretreatment to limit cycles of aggressive induction therapy with RHyperCVAD. 7. Dose does not exceed 400 mg (4 capsules or 4 tablets) per day, or the dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

    Prescribed regimen must be FDA-approved or recommended by NCCN.

    Initial Therapy: CLL/SLL

    Covered when ALL of the following are met

    CLL/SLL initial: 1. Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 2. Prescribed by or in consultation with an oncologist or hematologist. 3. Age ≥ 18 years. 4. For Calquence requests, member must use generic acalabrutinib if available unless contraindicated or clinically significant adverse effects are experienced. 5. Calquence is prescribed in one of the following ways: (a) first-line as a single agent; (b) first-line in combination with venetoclax (Venclexta), with or without obinutuzumab (Gazyva), only when the member does NOT have the del(17p)/TP53 mutation; (c) first-line in combination with obinutuzumab (Gazyva); (d) subsequent therapy (member has received ≥1 prior therapy) as single-agent for relapsed/refractory disease; (e) single-agent therapy for histologic transformation from CLL/SLL (Richter). 6. Member does not have Imbruvica-refractory CLL/SLL with BTK C481S mutations. 7. Request meets one of the following: (a) dose does not exceed 400 mg (4 capsules or 4 tablets) per day; or (b) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).Total duration ≤14 cycles when used with venetoclax for first-line in patients without del(17p)/TP53

    Prescribed regimen must be FDA-approved or recommended by NCCN; when combined with venetoclax/obinutuzumab follow specific cycle sequencing and durations per dosing guidance.

    Initial Therapy: Waldenstrom Macroglobulinemia / LPL (off‑label)

    Covered when ALL of the following are met

    WM/LPL off-label: 1. Diagnosis of Waldenstrom macroglobulinemia (WM) or lymphoplasmacytic lymphoma (LPL). 2. Prescribed by or in consultation with an oncologist or hematologist. 3. Age ≥ 18 years. 4. For Calquence requests, member must use generic acalabrutinib if available unless contraindicated or clinically significant adverse effects are experienced. 5. Calquence is prescribed as a single agent as second-line or subsequent therapy. 6. Calquence is not prescribed concurrently with Imbruvica (ibrutinib) or Brukinsa (zanubrutinib). 7. Request meets one of the following: (a) dose does not exceed 400 mg (4 capsules or 4 tablets) per day; or (b) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

    Prior authorization may be required; prescribed regimen must be FDA-approved or recommended by NCCN when applicable.

    Initial Therapy: Marginal Zone Lymphoma (off‑label)

    Covered when ALL of the following are met

    MZL off‑label: 1. Diagnosis of marginal zone lymphoma (MZL): (a) nodal MZL for relapsed, refractory, or progressive disease; OR (b) splenic MZL; OR (c) extranodal MZL (noncutaneous) for relapsed, refractory, or progressive disease. 2. Prescribed by or in consultation with an oncologist or hematologist. 3. Age ≥ 18 years. 4. For Calquence requests, member must use generic acalabrutinib if available unless contraindicated or clinically significant adverse effects are experienced. 5. Member has received ≥1 prior therapy. 6. Calquence is not prescribed concurrently with Imbruvica (ibrutinib) or Brukinsa (zanubrutinib). 7. Request meets one of the following: (a) dose does not exceed 400 mg (4 capsules or 4 tablets) per day; or (b) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

    Prior authorization may be required; prescribed regimen must be FDA-approved or recommended by NCCN when applicable.

    Continuation Therapy

    Covered when ALL of the following are met

    Continuation: 1. Member is currently receiving medication via the Centene benefit, or documentation supports that member has received Calquence for at least 30 days. 2. Member is responding positively to therapy. 3. For combination use with venetoclax as first-line therapy for CLL/SLL in members without the del(17p)/TP53 mutation, total duration of therapy will not exceed 14 cycles. 4. For Calquence requests, member must use generic acalabrutinib if available unless contraindicated or clinically significant adverse effects are experienced. 5. If request is for a dose increase, the new dose does not exceed 400 mg (4 capsules or 4 tablets) per day, or the new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).Approval duration: 12 months (or ≤14 total cycles for specified venetoclax combination)

    Prescribed regimen must be FDA-approved or recommended by NCCN.

    Coverage criteria (high-level)

    Covered when aligned with FDA approval and NCCN-supported indications and when dosing/regimen matches prescribing information:

    General dosing and formulation: Member will be prescribed acalabrutinib at recommended dosing (typically 100 mg PO twice daily) and not to exceed 400 mg/day; available 100 mg formulations (tablet or capsule) should be used as documented.

    See disease-specific dosing and sequencing guidance in the dosing section.

    CLL/SLL first-line combinations: Use as monotherapy or in combination per NCCN and FDA — includes combination with venetoclax (Venclexta) per 1Q2026 updates (only for patients without del(17p)/TP53) and combination with obinutuzumab (Gazyva) for previously untreated CLL/SLL; follow specific cycle sequencing when combined (e.g., start Calquence Cycle 1; start Gazyva Cycle 2; when used with venetoclax start Calquence Cycle 1 and venetoclax at Cycle 3).Total duration ≤14 cycles when used with venetoclax for first-line in patients without del(17p)/TP53

    Refer to dosing table for exact cycle timing.

    MCL indications: Use per NCCN and FDA approvals, including specified induction use in combination with rituximab for less aggressive induction; excludes use in Imbruvica-refractory MCL with BTK C481S mutation.

    Requests for non‑FDA approved indications that are not specifically addressed in this policy will be excluded unless the prescriber provides sufficient documentation of efficacy and safety in accordance with the payer's off‑label use policies (for example, CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, or CP.PMN.53 for Medicaid).

    The policy includes an explicit exclusion for Imbruvica‑refractory mantle cell lymphoma (MCL) with a BTK C481S mutation; use in that setting may be denied. In addition, the policy states that Calquence should not be prescribed concurrently with other BTK inhibitors (for example, Imbruvica or Brukinsa) in certain B‑cell indications such as Waldenström macroglobulinemia, LPL, and marginal zone lymphoma.

    Per the policy and supporting NCCN guidance, acalabrutinib (Calquence) lacks activity in ibrutinib‑refractory disease when a BTK C481S mutation is present; therefore use in ibrutinib‑refractory CLL/SLL or MCL with BTK C481S mutations is considered not appropriate.

    The policy clarifies that, in line with NCCN guidance, Calquence is not appropriate for Imbruvica‑refractory CLL/SLL if a BTK C481S mutation is present. This position was incorporated into the policy during routine updates to align with guideline recommendations.

    Coding

    Codes referencedmixed
    N/ANo explicit CPT/HCPCS/ICD-10/NDC codes listed in this part of the document
    Coding referenced but not listedmixed
    N/ADocument cites guideline and prescribing information updates but does not list specific CPT/HCPCS/NDC codes in this excerpt.
    Maximum daily dose — ≤ 400 mg/day
    Maximum daily dose≤ 400 mg/day (policy: dose does not exceed 400 mg per day or supported by guidelines)
    Typical regimen referenceMCL dosing regimen is 100 mg PO BID (section V: Dosage and Administration)
    FormulationsAvailable as 100 mg tablet or capsule (product availability)
    Maximum daily dose — 400 mg/day
    Maximum daily dose400 mg/day (policy: maximum dose specified for CLL/SLL and MCL)
    Dose exampleStandard dosing is 100 mg PO BID (total 200 mg/day), not to exceed 400 mg/day

    Provider Actions & Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Calquence (acalabrutinib) requests. Providers must submit documentation (office notes, labs, pathology, prior therapy details, mutation testing) that supports the member meets all applicable approval criteria, including diagnosis, prescriber specialty, age, prior therapies or specified combination regimens, and absence of excluded BTK C481S mutation where applicable. Requests for off‑label regimens must include supporting evidence (peer‑reviewed literature or guideline citations).

    • Affected indications: MCL, CLL/SLL, WM/LPL, MZL and other policy‑listed diagnoses
    • Authorization durations: initial approvals updated per policy (see policy header/criteria) — initial authorizations for Medicaid/HIM updated from 6 to 12 months where applicable
    • Off‑label use: prescriber must submit supporting evidence (guideline or literature)
    Documentation Required

    Dosing & Formulation Documentation

    Prescribers must document dosing regimen and product formulation on the PA submission. For MCL and CLL/SLL the usual dosing is 100 mg PO twice daily (maximum 400 mg/day). For combination regimens (e.g., with obinutuzumab or venetoclax) specify cycle timing and sequence per product labeling/NCCN (for example: start acalabrutinib 100 mg PO BID at Cycle 1 and start obinutuzumab at Cycle 2 when indicated; when used with venetoclax in frontline CLL/SLL, acalabrutinib is started at Cycle 1 and venetoclax at Cycle 3 per regimen guidance). Indicate whether tablet or capsule (100 mg) formulation will be used and note if generic acalabrutinib will be used unless contraindicated.

    Background

    Acalabrutinib (Calquence) is a Bruton tyrosine kinase (BTK) inhibitor indicated for adult patients with mantle cell lymphoma (MCL) and for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) per the product labeling and updated approvals. The policy notes that Calquence can be used in approved and certain NCCN‑supported regimens (including updated first‑line combinations in CLL/SLL), but it also documents limited activity in ibrutinib‑refractory disease with BTK C481S mutations and therefore excludes use in that molecular context.

    Definitions

    BTK C481S — BTK C481S mutation
    DefinitionBTK C481S — a mutation in Bruton tyrosine kinase (BTK) designated C481S
    Clinical relevanceAssociated with lack of activity of some BTK inhibitors in ibrutinib-refractory disease
    Reference sourceListed in policy appendices as abbreviation/key and discussed in Appendix D (general information)
    Induction therapy (MCL) — For MCL, policy specifies induction or maintenance and clarifies induction use in combination with rituximab
    Induction use (MCL)Policy permits acalabrutinib as induction therapy for MCL when prescribed in combination with rituximab for less aggressive induction therapy
    Alternative MCL combinationsAlso allowed in combination with bendamustine + rituximab for certain untreated patients ineligible for autologous HSCT

    Line of Therapy

    first-line | second-line | subsequent

    Lines: First-line (single agent or specified combinations), subsequent therapy (≥1 prior therapy), and specific second-line/subsequent uses for off-label indications

    first-line

    First-line CLL/SLL: Acalabrutinib used first-line as monotherapy or in combination with venetoclax or obinutuzumab per updated NCCN and FDA/PI guidance; when combined with obinutuzumab start Calquence at Cycle 1 and Gazyva at Cycle 2; when combined with venetoclax start Calquence at Cycle 1 and venetoclax at Cycle 3 for the specified durations; venetoclax combinations are restricted to patients without del(17p)/TP53 mutation.

    AMPLIFY trial results added to the Calquence PI; policy aligned to allow these regimens.

    second-line

    Biomarker & Mutation Requirements

    del(17p)/TP53 — must NOT have del(17p)/TP53 mutation for venetoclax combination in first‑line
    Biomarker requirementdel(17p)/TP53 — member must NOT have del(17p)/TP53 mutation to receive acalabrutinib + venetoclax in first-line CLL/SLL
    Regimen timingWhen used with venetoclax first-line, start acalabrutinib Cycle 1 and venetoclax at Cycle 3 per dosing guidance
    Duration limitTotal duration when combined with venetoclax in first-line CLL/SLL without del(17p)/TP53 is limited (policy: ≤14 cycles)
    BTK C481S — presence indicates ibrutinib‑refractory disease where acalabrutinib lacks activity
    Clinical implicationPresence of BTK C481S indicates ibrutinib-refractory disease where acalabrutinib lacks activity
    Policy action

    Covered Regimens and Dosing

    RegimenIndicationCoverage status
    Acalabrutinib 100 mg PO BID; monotherapy or in combination per FDA labeling
    Mantle cell lymphoma (MCL): as monotherapy for patients who have received ≥1 prior therapy, or in combination with bendamustine + rituximab for previously untreated patients who are ineligible for autologous HSCT
    Dose not to exceed 400 mg/day (4 capsules or 4 tablets) unless supported by guidelines or literature
    RegimenPatient selection / biomarker requirementDuration / Coverage status
    Acalabrutinib 100 mg PO BID in combination with venetoclax (with or without obinutuzumab)
    Previously untreated CLL/SLL without del(17p)/TP53 mutation
    Total duration when used with venetoclax in first-line (patients without del(17p)/TP53): not to exceed 14 cycles (Calquence up to 14 cycles; venetoclax total 12 cycles). Coverage: covered with criteria
    RegimenRestrictionsCoverage status
    Acalabrutinib 100 mg PO BID as single agent
    May be used off-label for Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) and marginal zone lymphoma (MZL) as second-line or subsequent therapy; must NOT be prescribed concurrently with ibrutinib (Imbruvica) or zanubrutinib (Brukinsa); prior authorization may be required
    Off-label use covered when criteria met; coverage with criteria (restricted)
    RegimenCycle timingCoverage status
    Calquence (acalabrutinib) 100 mg PO BID combined with obinutuzumab (Gazyva)
    Start Calquence at Cycle 1 (28-day cycles); start Gazyva at Cycle 2 for a total of 6 cycles; administer Calquence prior to Gazyva when given the same day
    Covered for previously untreated CLL/SLL per regimen and criteria
    RegimenCycle timing / durationCoverage status
    Calquence (acalabrutinib) 100 mg PO BID in combination with venetoclax
    Start Calquence at Cycle 1 (28-day cycles) for up to 14 cycles; start venetoclax at Cycle 3 for a total of 12 cycles
    Covered for previously untreated CLL/SLL without del(17p)/TP53 when criteria met; total duration not to exceed 14 cycles for Calquence
    ParameterValueNotes / Policy alignment
    Typical dosing regimen
    100 mg PO BID
    MCL and CLL/SLL standard dosing per prescribing information and policy (see dosing section).
    Policy Summary
    Payermhn
    PolicyAcalabrutinib (Calquence) coverage
    Policy CodePolicy CP.PHAR.366
    Change TypeMaterial updates (NCCN alignment, auth duration)
    Effective Date
    Next Review Date
    Key ActionPrescriber must submit documentation (office chart notes, lab results, or other clinical information) supporting that the member meets all approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & RequirementsBackgroundDefinitionsLine of TherapyBiomarker & Mutation RequirementsCovered Regimens and Dosing

    Authorization durations updated and maintenance use for MCL removed per recent updates.

    Other B-cell lymphomas: Policy includes NCCN off-label/compendia-supported uses for other B-cell lymphomas (WM, LPL, MZL) with requirements such as relapsed/refractory/progressive disease for certain subtypes and prohibition on concurrent prescription with other BTK inhibitors in some diagnoses.

    See disease-specific sections for per-disease restrictions.

    Authorization noteDose increases above 400 mg/day require supporting guidelines or literature and prior authorization
    • Standard dosing: 100 mg PO BID (tablet or capsule, 100 mg)
    • Maximum dose: 400 mg/day
    • Combination regimen documentation: specify cycle length, timing (which cycle each agent is initiated), and sequence
    Step Therapy

    Step Therapy / Prior BTK Inhibitor Requirements

    Step‑therapy and prior BTK inhibitor requirements: where prior‑therapy criteria apply, providers must document prior lines of therapy per the policy (see Appendix B for therapeutic alternatives). The policy excludes use for Imbruvica‑refractory disease with documented BTK C481S mutation for MCL and clarifies Calquence is not to be used in Imbruvica‑refractory CLL/SLL with BTK C481S mutations. The policy no longer universally requires prior trial of a BTK inhibitor before Calquence for all indications; check indication‑specific initial criteria (some indications may require ≥1 prior therapy or specific combination settings).

    • Therapeutic alternatives may be required — see Appendix B
    • Exclusion: Imbruvica‑refractory MCL or CLL/SLL with BTK C481S mutation — document mutation testing if claiming non‑refractory status
    • Prior BTK inhibitor: prior use of Imbruvica is not universally required; follow indication‑specific criteria
    RestrictionMember must not have Imbruvica-refractory MCL with BTK C481S mutations
    Relapsed/Refractory and later lines:
    Policy includes relapsed, refractory, or progressive disease requirements for certain nodal/extranodal MZL and other B-cell lymphomas and supports single-agent use following Richter transformation; off-label uses (WM/LPL, MZL) are limited to second-line or subsequent therapy as specified and concurrent prescription with other BTK inhibitors is prohibited in selected indications.

    Refer to disease-specific initial therapy sections for exact prior-therapy requirements and exclusions.

    Use in ibrutinib-refractory CLL/SLL or MCL with BTK C481S mutations is not appropriate (policy exclusion/denial risk)
    Guideline citationAppendix D notes lack of activity and references NCCN guidance for CLL/SLL and MCL
    BTK C481S mutation — (policy reference)
    Policy referencesBTK C481S mutation referenced in policy history and RT4 updates as basis for exclusions (Imbruvica-refractory MCL and some CLL/SLL contexts)
    Exclusion detailExclusion added for Imbruvica-refractory MCL with BTK C481S mutations; policy clarifies Calquence is not to be used in these scenarios
    Concurrent therapy notePolicy also added requirement that Calquence not be prescribed concurrently with Imbruvica or Brukinsa for certain B-cell lymphomas